Creatine and visceral fat is a topic attracting growing interest among fitness enthusiasts and clinicians alike. Creatine monohydrate is one of the UK's most popular sports supplements, widely used to support strength and exercise performance. Visceral fat — the metabolically active adipose tissue surrounding abdominal organs — is a key driver of cardiometabolic risk, including type 2 diabetes and cardiovascular disease. This article examines what the current evidence says about creatine's potential role in body composition, its safety profile in line with NHS and MHRA guidance, and the most effective lifestyle strategies for managing visceral fat.

What Is Creatine and How Is It Used in the UK?

Creatine monohydrate is the most researched and widely used sports supplement in the UK, regulated as a food supplement by the FSA and not prohibited by WADA. Typical protocols involve a loading phase of 20 g/day for 5–7 days, followed by a maintenance dose of 3–5 g/day.

Creatine is a naturally occurring compound synthesised primarily in the liver, kidneys, and pancreas from the amino acids arginine, glycine, and methionine. It is also obtained through dietary sources, particularly red meat and fish. Within the body, creatine is stored predominantly in skeletal muscle as phosphocreatine, where it plays a central role in the rapid regeneration of adenosine triphosphate (ATP) — the primary energy currency of cells — during short bursts of high-intensity exercise.

In the UK, creatine monohydrate is one of the most widely used sports supplements, available over the counter in health food shops, pharmacies, and online retailers. It is popular among athletes, bodybuilders, and recreational gym-goers seeking to improve strength, power output, and exercise recovery. Creatine monohydrate is the most extensively researched and best-evidenced form; other marketed variants (such as creatine ethyl ester or buffered creatine) have not demonstrated superiority in well-controlled trials. Creatine is not classified as a controlled drug under UK law and is not prohibited by the World Anti-Doping Agency (WADA Prohibited List, current year).

Typical supplementation protocols involve either a loading phase (20 g per day in divided doses for 5–7 days) followed by a maintenance phase (3–5 g per day), or a more gradual approach using 3–5 g daily from the outset.

In the UK, creatine supplements are regulated as food supplements by the Food Standards Agency (FSA), not as medicines. The MHRA may classify a product as a medicine if it is presented as treating or preventing disease, or if it exerts a pharmacological, immunological, or metabolic action by virtue of its composition — but standard creatine monohydrate products do not ordinarily meet this threshold. Nutrition and health claims on food supplements are controlled under the GB Nutrition and Health Claims Regulation. Because quality and purity can vary between products, consumers are advised to choose supplements carrying third-party quality certification; Informed Sport (a UK-based programme that tests for prohibited substances) is the most relevant certification for UK athletes, with NSF International as an additional option.

Understanding Visceral Fat and Its Health Risks

Visceral fat is metabolically active adipose tissue surrounding abdominal organs, strongly associated with metabolic syndrome, type 2 diabetes, and cardiovascular disease. NICE recommends waist circumference and waist-to-height ratio as practical clinical measures, with ethnicity-appropriate thresholds.

Visceral fat refers to adipose tissue stored deep within the abdominal cavity, surrounding vital organs such as the liver, pancreas, and intestines. Unlike subcutaneous fat — which lies just beneath the skin and can be pinched — visceral fat is metabolically active and releases a range of inflammatory cytokines, free fatty acids, and hormones that can disrupt normal physiological function. This distinguishes it as a particularly clinically significant form of body fat.

Excess visceral fat is strongly associated with a cluster of metabolic abnormalities collectively known as metabolic syndrome, which includes:

• Insulin resistance and type 2 diabetes

• Dyslipidaemia (elevated triglycerides and reduced HDL cholesterol)

• Hypertension

• Increased cardiovascular disease risk

NICE guidance on obesity assessment (including NICE CG189 and subsequent updates) recognises central adiposity as an independent risk factor for cardiometabolic disease. Waist circumference is recommended as a practical clinical measure alongside body mass index (BMI). For white European adults, a waist circumference above 94 cm in men and 80 cm in women indicates increased risk, with thresholds of 102 cm and 88 cm respectively denoting substantially elevated risk. These thresholds apply primarily to white European populations. Lower thresholds are appropriate for South Asian, Chinese, and other ethnic groups, in line with NICE guidance (including NICE PH46) and NHS advice — for example, a waist circumference above 80 cm in South Asian women and above 90 cm in South Asian men may indicate increased risk. Clinicians should apply ethnicity-appropriate thresholds when assessing individual patients.

NICE also recommends considering waist-to-height ratio in adults as a complementary measure; a ratio of 0.5 or above is generally used as a threshold indicating increased cardiometabolic risk.

Visceral fat accumulation is influenced by multiple factors, including physical inactivity, poor dietary quality, chronic stress, disrupted sleep, and hormonal changes associated with ageing. Because visceral fat is not directly visible, many individuals may be unaware of their risk. Healthcare professionals may use waist-to-hip ratio, waist-to-height ratio, or imaging techniques such as DXA scanning or MRI to assess visceral adiposity more precisely, though these are not routinely available in primary care settings.

What Does the Evidence Say About Creatine and Body Composition?

Creatine supplementation consistently increases lean muscle mass and may modestly reduce total fat mass when combined with exercise, but no direct evidence links it to visceral fat reduction specifically. Trials using imaging to measure visceral adipose tissue directly are limited and inconclusive.

The relationship between creatine supplementation and body composition — including visceral fat — is an area of growing scientific interest, though the evidence base remains nuanced and, in some respects, preliminary. The most consistently demonstrated effect of creatine supplementation is an increase in lean muscle mass, largely attributable to enhanced training capacity, improved muscle protein synthesis signalling, and intramuscular water retention (as creatine draws water into muscle cells). It is worth noting that this water retention can cause a modest increase in scale weight, which may mask improvements in body composition when total body mass alone is used as an outcome measure.

With regard to fat mass specifically, several studies have examined whether creatine supplementation, particularly when combined with resistance training, can reduce overall body fat percentage. A 2021 systematic review and meta-analysis (Lanhers et al. and related analyses published in the Journal of Strength and Conditioning Research) found modest reductions in fat mass in individuals supplementing with creatine alongside structured exercise programmes, compared to placebo groups. However, there is no established direct link between creatine supplementation and targeted reduction of visceral fat specifically; most studies have measured total body fat rather than visceral adiposity as a distinct compartment. Trials using imaging-based methods (DXA-derived visceral fat estimates or MRI) to assess visceral adipose tissue directly are limited, and firm conclusions cannot yet be drawn.

Some emerging research suggests that creatine may have indirect metabolic effects potentially relevant to visceral fat management:

• Improved insulin sensitivity, which may reduce visceral fat deposition over time

• Enhanced exercise performance, enabling greater training volumes that support fat loss

• Potential anti-inflammatory effects at the cellular level

These mechanistic observations are hypothesis-generating rather than established findings. The evidence in each area is limited and heterogeneous, and none has been demonstrated to produce clinically meaningful reductions in visceral adipose tissue in well-controlled human trials. The current evidence does not support the use of creatine as a standalone intervention for visceral fat reduction. Most researchers and clinicians agree that any body composition benefits observed are likely mediated through improved exercise capacity rather than a direct lipolytic or metabolic effect on visceral adipose tissue. Larger, well-controlled trials specifically measuring visceral fat via imaging are needed before firm conclusions can be drawn.

Safety Considerations and NHS Guidance on Creatine Use

Creatine monohydrate is safe in healthy adults at recommended doses, but it raises serum creatinine and should be avoided by those with pre-existing kidney disease. The NHS does not recommend creatine for under-18s, and users should inform their GP before blood tests.

Creatine monohydrate has a well-established safety profile when used at recommended doses in healthy adults. The International Society of Sports Nutrition (ISSN) Position Stand on Creatine has concluded that long-term supplementation (up to five years) appears safe in healthy individuals. The European Food Safety Authority (EFSA) has also reviewed creatine safety and considers supplemental intakes of approximately 3 g per day to be safe for the general adult population. It is important to note that the higher loading and maintenance doses commonly used in sports settings (up to 20 g/day during loading) are supported by sports science literature but exceed the intake level on which EFSA's general population safety conclusion is primarily based; individuals should be aware of this distinction.

Common, generally mild side effects associated with creatine supplementation include:

• Water retention and transient weight gain (due to intramuscular fluid shifts)

• Gastrointestinal discomfort, including bloating, nausea, or diarrhoea — particularly during loading phases

• Muscle cramping, though evidence for this is inconsistent

To reduce the risk of gastrointestinal symptoms during loading, doses should be split across the day and taken with food. Maintaining adequate hydration is also advisable, as creatine increases intramuscular water retention.

A frequently raised concern is the potential impact of creatine on renal function. Creatine is metabolised to creatinine, which is excreted by the kidneys, and supplementation can raise serum creatinine levels — a standard marker used in kidney function tests. This can produce misleading blood test results in otherwise healthy individuals; estimated glomerular filtration rate (eGFR) and clinical context should guide interpretation rather than serum creatinine alone. Current evidence does not support the notion that creatine supplementation causes kidney damage in people with normal renal function. That said, individuals with pre-existing kidney disease, a single kidney, or known renal impairment should avoid creatine supplementation and consult their GP or nephrologist before use.

The NHS does not formally recommend creatine supplementation as part of any clinical treatment pathway. Creatine is not recommended for under-18s, in line with NHS cautions regarding sports supplements in younger age groups. Patients should be advised to:

• Inform their GP if they are taking creatine, particularly before blood tests

• Seek medical advice before starting supplementation if they have any underlying health conditions

• Avoid products with unverified ingredients, as supplement adulteration remains a concern in the UK market

Pregnant or breastfeeding women are advised to avoid creatine supplementation due to insufficient safety data in these populations.

If you experience suspected side effects from a creatine supplement, these can be reported to the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk), which monitors the safety of medicines and supplements in the UK.

Lifestyle Approaches to Managing Visceral Fat Effectively

The most effective strategies for reducing visceral fat are sustained aerobic and resistance exercise, a Mediterranean-style diet, reduced alcohol intake, and improved sleep, consistent with NICE and CMO guidelines. Creatine may offer an adjunctive benefit by supporting greater training intensity within a structured exercise programme.

Whilst the interest in creatine and visceral fat is understandable, the most robustly evidenced strategies for reducing visceral adiposity remain rooted in sustainable lifestyle modification. NICE guidance consistently emphasises a multicomponent approach combining dietary change, increased physical activity, and behavioural support as the cornerstone of weight and fat management.

Physical activity is particularly effective at reducing visceral fat, even in the absence of significant changes in total body weight. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have demonstrated efficacy. Current recommendations from the UK Chief Medical Officers' (CMO) Physical Activity Guidelines — reflected in NHS guidance — advise adults to aim for:

• At least 150 minutes of moderate-intensity aerobic activity per week (or 75 minutes of vigorous-intensity activity)

• Muscle-strengthening activities on two or more days per week

Resistance training, in particular, increases skeletal muscle mass, which improves basal metabolic rate and insulin sensitivity — both of which are relevant to visceral fat reduction. This is the context in which creatine supplementation may offer an adjunctive benefit, by supporting greater training intensity and volume.

Dietary approaches with the strongest evidence for visceral fat reduction include:

• Reducing intake of ultra-processed foods, refined carbohydrates, and added sugars

• Adopting a Mediterranean-style dietary pattern, rich in vegetables, legumes, whole grains, oily fish, and unsaturated fats — broadly consistent with the principles of the NHS Eatwell Guide

• Moderating alcohol consumption, which is a significant contributor to central adiposity

Sleep quality and stress management are increasingly recognised as important modifiable factors. Chronic sleep deprivation and elevated cortisol levels — associated with prolonged psychological stress — promote visceral fat accumulation through hormonal pathways involving insulin and glucocorticoids.

Individuals concerned about their visceral fat levels or metabolic health are encouraged to speak with their GP, who can assess cardiovascular risk, arrange relevant investigations, and refer to structured weight management services where appropriate. In England, NHS Digital Weight Management Programmes and Tier 2 community weight management services are available for eligible patients. Eligibility criteria and referral thresholds for Tier 2–4 weight management services vary by locality and by the presence of comorbidities; patients should ask their GP or primary care team about locally available pathways.

Frequently Asked Questions